MedAI Verdict

AI Radiology · 58 tools

Editorial illustration: a chest radiograph alongside a magnifying glass highlighting flagged regions in blue.

Digital Diagnostics

Digital Diagnostics logo
30/ 100

Evidence & Documentation Score

This legacy score reflects documented evidence, integrations, transparency, and market signals. It does not measure overall product performance. A new product-focused rating system is in development. How it is computed

reviewed November 2, 2026

Vendor
Digital Diagnostics Inc., US
Pricing
No public price.
EHR
Not stated
Compliance
FDA 510(k), ISO 13485:2016 (vendor-stated, site footer)

Bottom line. LumineticsCore, formerly IDx-DR, screens retinal photographs for diabetic retinopathy and, in the vendor's description, makes the diagnosis without a physician reading the images. It is De Novo authorized as DEN180001, granted April 11, 2018, and two FDA-cleared 510(k) updates followed. The vendor's indication limits it to adults 22 or older with diabetes and no prior diagnosis of diabetic retinopathy, imaged… Read the full bottom line

Visit Digital Diagnostics (opens in new tab)

FDA 510(k) · ISO 13485:2016 (vendor-stated, site footer)

Performance profile

  • Regulatory and compliance18 / 28
  • Clinical integration0 / 6.6
  • Evidence strength0 / 26
  • Vendor and market3 / 12
  • Sentiment and transparency2.5 / 5

Performance profile

  • Regulatory and compliance18 / 28
  • Clinical integration0 / 6.6
  • Evidence strength0 / 26
  • Vendor and market3 / 12
  • Sentiment and transparency2.5 / 5
On this page

All 8 dimensions

Regulatory and compliance

  • FDA clearance18 / 18

    FDA authorized (2 510(k) clearances, 1 De Novo grant on record)

  • HIPAA / SOC2 / BAA0 / 10

    No public HIPAA/SOC2/BAA attestation

Clinical integration

  • EHR integrations (count)0 / 4.2

    No EHR integrations listed

  • Top-3 EHR coverage (Epic / Oracle / Athena)0 / 2.4

    None of the top-3 EHRs covered

Evidence strength

  • Peer-reviewed papers0 / 18.2

    No peer-reviewed paper evaluating the product

  • RCT / meta-analysis / systematic review0 / 7.8

    No RCT, meta-analysis, or systematic review evaluating the product

Vendor and market

  • Funding & adoption signal3 / 12

    Seed-stage or unfunded

Sentiment and transparency

  • Pricing transparency2.5 / 5

    Pricing on request, no public amounts

Computed November 6, 2026 by our public rubric. How it’s computed

What it costs

From
No public price.
Price points
1
Verified
November 2, 2026
Source
Vendor pricing page

All tiers are custom-quoted. The vendor does not publish per-provider list pricing.

TierMonthlyAnnualNotes
EnterpriseNot statedNot statedNo public price.

Source: vendor pricing page. Last checked November 2, 2026.

Compliance

Attested
FDA 510(k), ISO 13485:2016 (vendor-stated, site footer)
EHR integrations
Not stated
FDA
3 decisions on record

Carries FDA 510(k), ISO 13485:2016 (vendor-stated, site footer) per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment.

Vendor stability

Company
Digital Diagnostics Inc.
Headquarters
US
Founded
Not stated
Formerly known as
IDx-DR

It was previously known as IDx-DR, an acquisition or rebrand that healthcare-AI buyers should track when reviewing prior independent coverage.

Vendor sitewww.digitaldiagnostics.com (opens in new tab)

Evidence record

RecordWhat we found
FDA decisions
Verification
  • Score computed November 6, 2026, method 1.2.1
  • Review written November 2, 2026
Cite this record

MedAI Verdict, Digital Diagnostics record, https://medaiverdict.com/tools/digital-diagnostics, version November 2, 2026

Change historyView every change to this record

Bottom line

LumineticsCore, formerly IDx-DR, screens retinal photographs for diabetic retinopathy and, in the vendor's description, makes the diagnosis without a physician reading the images. It is De Novo authorized as DEN180001, granted April 11, 2018, and two FDA-cleared 510(k) updates followed. The vendor's indication limits it to adults 22 or older with diabetes and no prior diagnosis of diabetic retinopathy, imaged with a Topcon NW400. It fits a primary care clinic screening that population. The vendor's indication names the Topcon NW400, and other cameras are not stated on its pages. The vendor sells only to healthcare providers and quotes no price.

LumineticsCore: De Novo authorized autonomous AI that detects more than mild diabetic retinopathy from retinal photos.

No public price.

What does the vendor say LumineticsCore does?

In the vendor's description, an operator takes two images per eye and submits them, and the result returns within 30 seconds. The vendor states the indication as detecting more than mild diabetic retinopathy, abbreviated mtmDR, and says it was the first company to receive FDA clearance for an AI diagnostic platform that makes a diagnosis without physician input. Its outcome claims include 91% of unnecessary specialty visits avoided in its trial for FDA authorization, eye exam adherence rising from 12% to 30% at Zufall Health, and diabetic retinopathy diagnosed in more than one in four patients tested at Cahaba Medical Care within 90 days. Other customers it names are Tarzana Treatment Centers, Johns Creek Primary Care, OSF HealthCare, Urban Health Plan and AbsoluteCare.

What does the De Novo decision cover?

DEN180001 is IDx-DR, requested by IDx, LLC of Iowa City under product code PIB, "diabetic retinopathy detection device," 21 CFR 886.1100. FDA received it on January 12, 2018 and granted it as a Class II device on April 11, 2018. The FDA-cleared follow-ups are K203629 (June 10, 2021) and K213037 (IDx-DR v2.3, June 17, 2022), both under PIB. FDA's records still use the IDx-DR name and none carries the name LumineticsCore.

The vendor lists CPT 92229 as the reimbursement code. By its account the code was created in 2019, CMS proposed a rule on it in August 2020, and in early 2023 CMS changed the wording from "automated" to "autonomous diagnosis."

What do the published studies report?

A systematic review and meta-analysis of IDx-DR accuracy reports a pooled AUC of 0.95 (PMID 39986640). A comparison of Mona DR and IDx-DR against human grading reports a kappa of 0.43, described as moderate, for IDx-DR and 0.68 for Mona DR. A real-world comparison with ophthalmologist fundoscopy grading reports an exact match of 54.2% and undergrading of 4.8%. The vendor's product page gives no sensitivity or specificity.

The verdict

LumineticsCore suits a primary care clinic that screens adults with diabetes on the Topcon NW400 and wants an autonomous result under CPT 92229, the code the vendor lists as reimbursable. The vendor sells only to healthcare providers.

Editorial review last generated November 2, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.

Link to this review

Digital Diagnostics, reviewed on MedAI Verdict

Vendors may place this badge on their own site. It links to this review with a tracking parameter and has no effect on the score.

<a href="https://medaiverdict.com/tools/digital-diagnostics?utm_source=vendor_badge&utm_medium=badge&utm_campaign=digital-diagnostics"><img src="https://medaiverdict.com/badges/reviewed-on-medaiverdict.png" srcset="https://medaiverdict.com/badges/reviewed-on-medaiverdict@2x.png 2x" alt="Digital Diagnostics, reviewed on MedAI Verdict" width="200" height="56"></a>

What we have not verified

  1. We have not run Digital Diagnostics in our own clinical practice. Pricing, certifications, and EHR-integration claims come from vendor documentation and have not been independently audited.
  2. Enterprise pricing tiers and SLA terms are typically under NDA and not publicly verifiable. Numbers shown reflect publicly disclosed self-service or list pricing only.
  3. Real-world latency, note quality, and accuracy in your specific specialty and patient population can vary materially from vendor demonstrations. We recommend a 30-day trial with two providers before commitment.

Last verified . Read our methodology · Radiology